IGMS
IGM Biosciences Inc
$17.02
Earnings Summary
Revenue | $0.33Mn |
Net Profits | $-58.04Mn |
Net Profit Margins | -17533.84% |
Highlights
IGM Biosciences Inc’s revenue jumped +Inf% since last year same period to $0.33Mn in the Q3 2022. On a quarterly growth basis, IGM Biosciences Inc has generated -9.56% fall in its revenue since last 3-months.
IGM Biosciences Inc’s net profit fell -31.41% since last year same period to $-58.04Mn in the Q3 2022. On a quarterly growth basis, IGM Biosciences Inc has generated 0.95% jump in its net profits since last 3-months.
IGM Biosciences Inc’s net profit margin jumped NaN% since last year same period to -17533.84% in the Q3 2022. On a quarterly growth basis, IGM Biosciences Inc has generated -9.52% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the IGM Biosciences Inc post its latest quarter earnings
EPS Estimate Current Quarter | -1.25 |
EPS Estimate Current Year | -1.25 |
Highlights
IGM Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -1.25 - a 12.59% jump from last quarter’s estimates.
IGM Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -1.25.
Key Ratios
Key ratios of the IGM Biosciences Inc post its Q3 2022 earnings
Earning Per Share (EPS) | -1.32 |
Return on Assets (ROA) | -0.32 |
Return on Equity (ROE) | -0.71 |
Highlights
IGM Biosciences Inc’s earning per share (EPS) jumped 0% since last year same period to -1.32 in the Q3 2022. This indicates that the IGM Biosciences Inc has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. IGM Biosciences Inc’s return on assets (ROA) stands at -0.32.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. IGM Biosciences Inc’s return on equity (ROE) stands at -0.71.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2019-11-07 | -0.82 | -2.41 | -193.9% |
2020-03-26 | -0.43 | -0.49 | -13.95% |
2019-06-30 | 0 | -2.69 | -Inf% |
Company Information
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Organisation | IGM Biosciences Inc |
Headquarters | 325 East Middlefield Road, Mountain View, CA, United States, 94043 |
Employees | 242 |
Industry | Health Technology |
